New weekly combo shows promise for Hard-to-Treat lymphoma
NCT ID NCT01703949
First seen May 12, 2026 · Last updated May 23, 2026 · Updated 3 times
Summary
This study tests whether giving a targeted drug (brentuximab vedotin) weekly, with or without another immune-boosting drug (nivolumab), can shrink tumors in people with CD30+ lymphoma that has come back or stopped responding to standard treatment. About 28 adults with relapsed or refractory Hodgkin or non-Hodgkin lymphoma will take part. The goal is to see if the weekly schedule or the combination can improve response rates.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY HODGKIN LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109, United States
Conditions
Explore the condition pages connected to this study.